Recent Updates
Recently added Catalysts
XTNT

Bacterin to Showcase New Product Line at the North American Spine Society Annual Meeting BELGRADE, MT--(BUSINESS WIRE)

Key Takeaway: Bacterin to Showcase New Product Line at the North American Spine Society Annual Meeting BELGRADE, MT--(BUSINESS WIRE) - November 4, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and bioactive coatings for me

Full Press Release Details

Bacterin to Showcase New Product Line
at the North American Spine Society Annual Meeting
BELGRADE, MT--(BUSINESS WIRE) - November 4, 2014 -- Bacterin
International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and bioactive coatings for medical
applications, today announced the first public presentation of a unique new product line for use in spinal procedures, the 3Demin
product family, which will be displayed at the 2014 North American Spine Society (NASS) Annual Meeting.
The NASS Annual Meeting is renowned as, "The
world's largest spine meeting and exhibition." Bacterin's 3Demin product family will be showcased
to a targeted spine demographic that is influential in surgical supply purchasing decisions. The new 3Demin line
of products will be featured at Bacterin's booth, number 2004. The NASS Annual Meeting Scientific Exhibits will be open November
12th - 13th 9:00AM - 5:00PM PST, and November 14th 9:00AM -1:30PM
PST at the Moscone Center in San Francisco, CA.
Bacterin's executive officers will be on hand to answer
questions about Bacterin's spine product portfolio including OsteoSponge , OsteoSelect DBM
Putty, OsteoWrap , OsteoSTX , and the new 3Demin product family. In attendance will be Dan
Goldberger, CEO; Robert DiSilvio, President; Gregory Juda, CSO; and Melanie Head, VP of Sales.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE
MKT: BONE) develops, manufactures and markets biologic products to domestic and international markets. These products are used
in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot
and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division
develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant
risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer
to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," "projects," "forecasts,"
"strategy," "will," "goal," "target," "prospects," "potential," "optimistic,"
"confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical
fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties,
and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability
to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the
Company's secured lending facility; the Company's ability to manage cash flow and achieve profitability; the Company's
ability to remain listed on the NYSE MKT; the Company's ability to develop, market, sell and distribute desirable applications,
products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results;
the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as
and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees
with appropriate skills and expertise; the Company's ability to successfully conclude government investigations; the impact
of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors;
and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form
10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any
forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events, except as required by law.
Last updated: Nov 4, 2014